Performance comparison of the cobas Liat and Cepheid GeneXpert systems for Clostridium difficile detection

PLoS ONE

Volumn 13, Issue 7, 2018, Pages

  Granato, Paul A ^a   Hansen, Glen ^b   Herding, Emily ^b   Chaudhuri, Sheena ^c   Tang, Shaowu ^c   Garg, Sachin K ^c   Rowell, Catherine R ^a   Sickler, Joanna Jackson ^c  

^a Laboratory Alliance of Central New York   (United States)

^b HENNEPIN COUNTY MEDICAL CENTER   (United States)

^c Medical and Scientific Affairs   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BACTERIAL LOAD; BACTERIUM DETECTION; COMPARATIVE STUDY; CONTROLLED STUDY; FECES ANALYSIS; GENE; HUMAN; NONHUMAN; PEPTOCLOSTRIDIUM DIFFICILE; POLYMERASE CHAIN REACTION; PROSPECTIVE STUDY; TCDB GENE; CLOSTRIDIUM INFECTION; DIAGNOSTIC TEST; FECES; GENETICS; ISOLATION AND PURIFICATION; MICROBIOLOGY; MOLECULAR DIAGNOSIS; SENSITIVITY AND SPECIFICITY;

BACTERIAL PROTEIN; BACTERIAL TOXIN; ENTEROTOXIN;

BACTERIAL PROTEINS; BACTERIAL TOXINS; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; DIAGNOSTIC TESTS, ROUTINE; ENTEROTOXINS; FECES; HUMANS; MOLECULAR DIAGNOSTIC TECHNIQUES; POLYMERASE CHAIN REACTION; PROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY;

EID: 85050497598     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0200498     Document Type: Article

References (23)

1. Magill SS, Edwards JR, Fridkin SK; Emerging Infections Program Healthcare-Associated Infections and Antimicrobial Use Prevalence Survey Team. Survey of health care-associated infections. N Engl J Med. 2014; 370: 2542–2543.
2. Leffler DA, Lamont JT. Clostridium difficile infection. N Engl J Med. 2015; 372: 1539–1548. https://doi.org/10.1056/NEJMra1403772 PMID: 25875259
3. Bartlett JG. Clinical practice. Antibiotic-associated diarrhea. N Engl J Med. 2002; 346: 334–339. https://doi.org/10.1056/NEJMcp011603 PMID: 11821511
4. Lessa FC, Winston LG, McDonald LC; Emerging Infections Program C. difficile Surveillance Team. Burden of Clostridium difficile infection in the United States. N Engl J Med. 2015; 372: 2369–2370. https://doi.org/10.1056/NEJMc1505190 PMID: 26061850
5. Cohen SH, Gerding DN, Johnson S, Kelly CP, Loo VG, McDonald LC, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol. 2010; 31: 431–455. https://doi.org/10.1086/651706 PMID: 20307191
6. Surawicz CM, Brandt LJ, Binion DG, Ananthakrishnan AN, Curry SR, Gilligan PH, et al. Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. Am J Gastroenterol. 2013; 108: 478–98; quiz 499. https://doi.org/10.1038/ajg.2013.4 PMID: 23439232
7. Butler M, Olson A, Drekonja D, Shaukat A, Schwehr N, Shippee N, et al. Early Diagnosis, Prevention, and Treatment of Clostridium difficile: Update. Rockville, MD: Agency for Healthcare Research and Quality; 2016.
8. Chapin KC, Dickenson RA, Wu F, Andrea SB. Comparison of five assays for detection of Clostridium difficile toxin. J Mol Diagn. 2011; 13: 395–400. https://doi.org/10.1016/j.jmoldx.2011.03.004 PMID: 21704273
9. ® 4800 System. Eur J Microbiol Immunol (Bp). 2017; 7: 310–318.
10. Berrington A, Settle CD. Which specimens should be tested for Clostridium difficile toxin? J Hosp Infect. 2007; 65: 280–282.
11. Dionne LL, Raymond F, Corbeil J, Longtin J, Gervais P, Longtin Y. Correlation between Clostridium difficile bacterial load, commercial real-time PCR cycle thresholds, and results of diagnostic tests based on enzyme immunoassay and cell culture cytotoxicity assay. J Clin Microbiol. 2013; 51: 3624–3630. https://doi.org/10.1128/JCM.01444-13 PMID: 23966497
12. Paitan Y, Miller-Roll T, Adler A. Comparative performance study of six commercial molecular assays for rapid detection of toxigenic Clostridium difficile. Clin Microbiol Infect. 2017; 23: 567–572. https://doi.org/10.1016/j.cmi.2017.02.016 PMID: 28223147
13. Dalpke AH, Hofko M, Zorn M, Zimmermann S. Evaluation of the fully automated BD MAX Cdiff and Xpert C. difficile assays for direct detection of Clostridium difficile in stool specimens. J Clin Microbiol. 2013; 51: 1906–1908. https://doi.org/10.1128/JCM.00344-13 PMID: 23515539
14. Le Guern R, Herwegh S, Courcol R, Wallet F. Molecular methods in the diagnosis of Clostridium difficile infections: an update. Expert Rev Mol Diagn. 2013; 13: 681–692. https://doi.org/10.1586/14737159.2013.829705 PMID: 24063396
15. Viala C, Le Monnier A, Maataoui N, Rousseau C, Collignon A, Poilane I. Comparison of commercial molecular assays for toxigenic Clostridium difficile detection in stools: BD GeneOhm Cdiff, Xpert C. difficile and illumigene C. difficile. J Microbiol Methods. 2012; 90: 83–85. https://doi.org/10.1016/j. mimet.2012.04.017 PMID: 22565213
16. Shin BM, Yoo SM, Shin WC. Evaluation of Xpert C. difficile, BD MAX Cdiff, IMDx C. difficile for Abbott m2000, and illumigene C. difficile assays for direct detection of toxigenic Clostridium difficile in stool specimens. Ann Lab Med. 2016; 36: 131–137. https://doi.org/10.3343/alm.2016.36.2.131 PMID: 26709260
17. Senchyna F, Gaur RL, Gombar S, Truong CY, Schroeder LF, Banaei N. Clostridium difficile PCR cycle threshold predicts free toxin. J Clin Microbiol. 2017; 55: 2651–2660. https://doi.org/10.1128/JCM. 00563-17 PMID: 28615471
18. Shin S, Kim M, Kim M, Lim H, Kim H, Lee K, et al. Evaluation of the Xpert Clostridium difficile assay for the diagnosis of Clostridium difficile infection. Ann Lab Med. 2012; 32: 355–358. https://doi.org/10.3343/alm.2012.32.5.355 PMID: 22950071
19. Seo JY, Jeong JH, Kim KH, Ahn JY, Park PW, Seo YH. Laboratory diagnosis of Clostridium difficile infection: Comparison of Techlab C. diff Quik Chek Complete, Xpert C. difficile, and multistep algorithmic approach. J Clin Lab Anal. 2017; 31: https://doi.org/10.1002/jcla.22135 PMID: 28177534
20. Tenover FC, Novak-Weekley S, Woods CW, Peterson LR, Davis T, Schreckenberger P, et al. Impact of strain type on detection of toxigenic Clostridium difficile: comparison of molecular diagnostic and enzyme immunoassay approaches. J Clin Microbiol. 2010; 48: 3719–3724. https://doi.org/10.1128/JCM.00427-10 PMID: 20702676
21. Peterson LR, Young SA, Davis TE Jr, Wang ZX, Duncan J, Noutsios C, et al. Evaluation of the cobas Cdiff Test for detection of toxigenic Clostridium difficile in stool samples. J Clin Microbiol. 2017; 55: 3426–3436. https://doi.org/10.1128/JCM.01135-17 PMID: 28954901
22. Gilbreath JJ, Verma P, Abbott AN, Butler-Wu SM. Comparison of the Verigene Clostridium difficile, Sim-plexa C. difficile Universal Direct, BD MAX Cdiff, and Xpert C. difficile assays for the detection of toxigenic C. difficile. Diagn Microbiol Infect Dis. 2014; 80: 13–18. https://doi.org/10.1016/j.diagmicrobio.2014.06.001 PMID: 25027069
23. Yoo J, Lee H, Park KG, Lee GD, Park YG, Park YJ. Evaluation of 3 automated real-time PCR (Xpert C. difficile assay, BD MAX Cdiff, and IMDx C. difficile for Abbott m2000 assay) for detecting Clostridium difficile toxin gene compared to toxigenic culture in stool specimens. Diagn Microbiol Infect Dis. 2015; 83: 7–10. https://doi.org/10.1016/j.diagmicrobio.2015.05.005 PMID: 26081240